Search Results

You are looking at 1 - 10 of 108 items for

  • Author or Editor: W. W. Muir x
  • Refine by Access: All Content x
Clear All Modify Search

SUMMARY

Objective

To determine the maximal IV administered dose of propofol that would not induce a serious adverse event in nonsedated dogs.

Animals

6 clinically normal dogs (3 males and 3 females) between 8 and 12 months old and weighing between 8.8 and 11.3 kg.

Procedure

Propofol was administered IV at an initial dosage of 6.5 mg/kg of body weight at a rate of 20 mg/10 s. Subsequent doses were incrementally increased by 2.5 mg/kg (eg, second dose: 9 mg/kg) and separated by a minimum of 3 days. This procedure was repeated until a dose that induced a serious respiratory, cardiovascular, or neurologic adverse effect was determined.

Results

Apnea was determined to be the serious adverse effect for all dogs. Duration of apnea varied between dogs, but increased in a dose-dependent manner at dosages > 14 mg/kg.

Conclusions

Respiratory depression and apnea are the most likely adverse effects induced by IV administration of propofol to dogs. Propofol administered IV at a rate of 20 mg/kg/10 s induces minimal cardiovascular depression at dosages in excess of the apneic dosage.

Clinical Relevance

Respiratory depression and apnea should be expected as potential adverse effects after IV administration of propofol to dogs, particularly when administered at rapid rates of infusion. (Am J Vet Res 1998:59:157–161)

Free access
in American Journal of Veterinary Research

SUMMARY

Objective

To determine and compare cardiorespiratory and recovery effects of sevoflurane, isoflurane, and halothane in horses.

Animals

8 clinically normal horses (4 mares, 4 geldings), 5 to 12 years old.

Procedure

Inhalation anesthesia was maintained for 90 minutes with sevoflurane, isoflurane, or halothane. Anesthesia depth was maintained at 1.5 minimum alveolar concentration of halothane, isoflurane, and sevoflurane, then was reduced at 30 and 60 minutes. A surgical plane of anesthesia was reinduced by administration of ketamine or thiopental or by increasing the fractional inspired concentration of sevoflurane. Cardiovascular and pulmonary variables were recorded and compared among inhalation anesthetics. Recovery was monitored, and subjective assessment of recovery quality was performed.

Results

Hemodynamic and pulmonary indices during sevoflurane anesthesia were similar to those of isoflurane. Cardiac output and systemic arterial pressure decreased less during sevoflurane and isoflurane anesthesia than during halothane anesthesia. After 90 minutes, cardiac output was greater for sevoflurane and isoflurane, respectively, compared with halothane. Mean arterial pressure was similar for all thre anesthetic agents. Respiratory rate for sevoflurane and isoflurane was less than that for halothane. This apparent respiratory depression correlated with greater increase in Paco2 and decreased pH when sevoflurane and isoflurane were compared with halothane. Recovery from sevoflurane anesthesia was qualitatively similar and superior to recovery from isoflurane and halothane, respectively. Time to standing did not differ significantly between sevoflurane and isoflurane, but was shorter than halothane.

Conclusions

Sevoflurane induced cardiorespiratory effects that were comparable to those of isoflurane and halothane. Cardiac output was greater and respiratory rate was less than that for halothane at 1.5 MAC. Sevoflurane anesthesia was characterized by good control of anesthesia depth during induction, maintenance, and recovery. Recovery time after sevoflurane anesthesia was comparable to that for isoflurane, and recovery was smooth and controlled in a manner consistent with recovery from halothane. (Am J Vet Res 1998;59:101–106)

Free access
in American Journal of Veterinary Research
in Journal of the American Veterinary Medical Association

Abstract

Objectives

To determine the concentrations of sevoflurane and compound A (a degradation product of sevoflurane) in the anesthetic circuit when sevoflurane was delivered with an in-circuit vaporizer, and to determine the cardiorespiratory effects of sevoflurane in dogs.

Animals

6 mixed-breed dogs.

Procedure

In-circuit vaporizers were connected to the inspiratory limb of a circle rebreathing system connected to a ventilator. A reservoir bag was attached to the Y-piece connector to act as an artificial lung, and sevoflurane concentrations in the anesthetic circuit were measured at vaporizer settings of 1, 3, 5, 7, and 10 and oxygen flow rates of 250 and 500 ml/min. Cardiorespiratory effects of sevoflurane were determined in dogs while they were breathing spontaneously, during controlled ventilation, and during closed circuit anesthesia. Concentrations of compound A were determined by means of gas chromatography with flame ionization.

Results

The concentration of sevoflurane in the anesthetic circuit increased with vaporizer setting and time. For oxygen flow rates of 250 and 500 ml/min, vaporizer settings between 5 and 7 and between 7 and 10, respectively, produced sevoflurane concentrations closest to values reported to produce surgical anesthesia in dogs. Significant differences were not observed in cardiorespiratory variables with time or among anesthetic conditions. Concentrations of compound A in the anesthetic circuit were less than values reported to produce renal toxicoses and death in rats.

Conclusion

Results suggested that sevoflurane can be administered to nonsurgically stimulated dogs, using an in-circuit vaporizer and low (< 15 ml/kg/min) oxygen flow rates, without causing significant cardiorespiratory depression or clinically important concentrations of compound A. (Am J Vet Res 1998;59:603–608)

Free access
in American Journal of Veterinary Research

Summary

Mechanisms responsible for the positive inotropic effects of dopexamine were investigated in 8 halothane-anesthetized horses. The hemodynamic effects of increasing infusions of dopexamine (5, 10, 15 μg/kg of body weight/min) were determined before and after sequential administration of specific antagonists. Using glycopyrrolate and chlorisondamine, and atenolol and ICI 118,551, muscarinic and nicotinic ganglionic, and β1, and β2-adrenergic receptor blockade, respectively, was induced. Dopexamine infusions induced increase in heart rate, cardiac output, systolic and mean arterial blood pressure, and maximal rate of left ventricular pressure development (+ dP/dtmax). Right atrial pressure and systemic vascular resistance decreased. Parasympathetic and ganglionic blockade attenuated cardiac output, systolic and mean aortic blood pressures, and + dP/dtmax responses to dopexamine infusion. Dopexamine-induced increase in heart rate was potentiated by parasympathetic and ganglionic blockade. β1-Adrenergic receptor blockade decreased heart rate, cardiac output, arterial blood pressure, and + dP/dtmax from baseline values and markedly reduced the response to dopexamine infusion. β2-Adrenergic receptor blockade induced further decrease in hemodynamic variables from baseline values and completely abolished the cardiostimulatory effects of dopexamine on + dP/dtmax. These data indicate that baroreflex activity, β1- and β2-adrenergic receptor stimulation may be an important cause of dopexamine's positive inotropic effects in horses.

Free access
in American Journal of Veterinary Research

Objective

Evaluation of a portable clinical analyzer for determination of blood gas tensions, electrolyte and glucose concentrations, and Hct in a hospital setting.

Design

Prospective study.

Animals

50 dogs, 50 cats, and 28 horses, all clinically normal.

Procedure

Blood samples were analyzed on a portable clinical analyzer to determine concentrations of sodium, potassium, chloride, BUN, glucose, and ionized calcium and values of Hct, pH, Pco2, and Po2. Values obtained were compared with those obtained from the same blood samples, using a standard automatic analyzer (serum sodium, potassium, chloride, BUN, and glucose concentrations), a cell counter (Hct), a blood gas analyzer (pH, Pco2, Po2), and a calcium-pH analyzer (ionized calcium). Bias (mean difference between values obtained on the same sample by different methods) and variability (SD of differences) were determined for all values. Data were also subjected to Deming regression analysis.

Results

Correlation coefficients were > 0.90 for all values except potassium and ionized calcium concentrations. Bias and variability were within clinically acceptable limits (± 2 SD) for all but potassium, ionized calcium, and glucose concentrations and Hct. Species-dependent variability was observed for glucose concentration and Hct.

Clinical Implications

Most differences between values obtained with the portable clinical analyzer and standard clinical laboratory systems could be accounted for by differences in type of sample tested (blood vs serum). The portable clinical analyzer is suitable for point-of-care analysis in critical care situations and for routine blood biochemical analysis when extensive laboratory support is unavailable. (J Am Vet Med Assoc 1998;213:691-694)

Free access
in Journal of the American Veterinary Medical Association

SUMMARY

Objective

To determine reliability of noninvasive methods of arterial oxyhemoglobin saturation (SpO2 ), end-tidal CO2 concentration (PEtCO2 and blood pressure (BP) determination during periods of hypoxemia and systemic arterial BP perturbations.

Animals

7 healthy, conditioned dogs weighing 19 to 22 kg.

Procedure

3 pulse oximeters, 2 capnometers, and 2 oscillometric BP monitors were used to measure oxygen-carrying capacity of the blood, heart rate, ventilatory status and arterial BP changes during hypoxemia, and altered arterial BP. Pulse oximeter-derived SpO2 and PEtCO2 were determined during rapidly induced plateaus of hypoxia (decreased fractional inspired oxygen concentration [FiO2 ) and altered systemic arterial BP. A lead-II ECG was used to monitor heart rate.

Results

Pulse oximetry provided an accurate assessment of fractional oxyhemoglobin saturation (SaO2 ) at SpO2 > 70%. As SaO2 decreased from 70%, the magnitude of the SpO2 error increased (20% error at SpO2 < 30%). The PEtCO2 was accurate at PaCO2 , ranging from 30 to 55 ± 5 mm of Hg under all experimental conditions. When PaCO2 was > 55 mm of Hg, both capnometers produced values that were as much as 20 mm of Hg less than the corresponding PaCO2 . Mean BP was least dependent on pulse wave quality, consistently underestimating mean arterial BP by approximately 10 mm of Hg.

Conclusions and Clinical Relevance

The pulse oximeters tested provided an accurate estimation of SaO2 at SpO2 > 70%. A PEtCO2 value > 55 mm of Hg may represent hypercapnia that is more profound than indicated. Systolic BP determinations were most accurate during hypotensive states and least accurate during hypertension. Diastolic BP measurements were generally more accurate during hypertension than normotension. Accuracy is not appreciably affected by hypotension resulting from vasodilation or blood loss. The tendency to underestimate systemic arterial BP should not interfere with trend detection during unstable clinical conditions. (Am J Vet Res 1998;59:205–212)

Free access
in American Journal of Veterinary Research

Abstract

Objective—To determine the effects of xylazine on canine coronary artery smooth muscle tone.

Sample Population—Hearts of 26 healthy dogs.

Procedure—Dogs were anesthetized with pentobarbital, and vascular rings of various diameters were prepared from the epicardial coronary arteries. Vascular rings were placed in tissue baths to which xylazine was added (cumulative concentrations ranging from 10–10 to 10–4M), and changes in vascular ring tension were continuously recorded. Effects of the nitric oxide inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 5mM), the α1-adrenoceptor antagonist prazosin (10mM), and the α2-adrenoceptor antagonist atipamezole (10mM) on xylazine-induced changes in vascular ring tension were determined. Results were expressed as percentage of maximal contraction for each vascular ring preparation.

Results—Xylazine induced vasoconstriction of small (< 500-µm-diameter) and medium (500- to 1,000-µmdiameter) vascular rings but not of large (> 1,000-µmdiameter) rings. For large vascular rings, L-NAME, atipamezole, and prazosin did not significantly affect the contractile response to xylazine. For small vascular rings, the contractile response following addition of xylazine to rings treated with L-NAME was not significantly different from the contractile response following addition of xylazine to control rings, except at a xylazine concentration of 10–6M. Xylazine-induced vasoconstriction of small vascular rings was blocked by atipamezole, but the addition of prazosin had no effect on xylazine-induced vasoconstriction.

Conclusions and Clinical Relevance—Results suggest that xylazine increases smooth muscle tone of small canine coronary arteriesand that this effect is predominantly mediated by stimulation of α2adrenoceptors.( Am J Vet Res 2004;65:431–435)

Full access
in American Journal of Veterinary Research

Abstract

Objective— To determine the hemodynamic effects of IM administration of romifidine hydrochloride in propofol-anesthetized cats.

Animals—15 adult domestic shorthair cats.

Procedure—Cats were randomly assigned to receive romifidine (0, 400, or 2,000 µg/kg, IM). Cats were anesthetized with propofol and mechanically ventilated with oxygen. The right jugular vein, left carotid artery, and right femoral artery and vein were surgically isolated and catheterized. Heart rate; duration of the PR, QRS, and QT intervals; mean pulmonary artery pressure; mean right atrial pressure; systolic, diastolic, and mean arterial pressures; left ventricular systolic pressure; left ventricular end-diastolic pressure; and cardiac output were monitored. Systemic vascular resistance, rate of change of left ventricular pressure, and rate pressure product were calculated. Arterial and venous blood samples were collected anaerobically for determination of pH and blood gas tensions (PO2 and PCO2).

Results—Administration of romifidine at 400 and 2,000 µg/kg, IM, decreased heart rate, cardiac output, rate of change of left ventricular pressure, rate pressure product, and pH. Arterial and pulmonary artery pressures, left ventricular pressure, left ventricular end-diastolic pressure, and right atrial pressure increased and then gradually returned to baseline values. Arterial blood gas values did not change, whereas venous PCO2 increased and venous PO2 decreased. Significant differences between low and high dosages were rare, suggesting that the dosages investigated produced maximal hemodynamic effects.

Conclusion and Clinical Relevance—Romifidine produces cardiovascular effects that are similar to those of other α2-agonists. High dosages of romifidine should be used with caution in cats with cardiovascular compromise. (Am J Vet Res 2002;63:1241–1246)

Full access
in American Journal of Veterinary Research

Abstract

Objective—To evaluate the effects of the α2-adrenoceptor agonist medetomidine on respiratory rate (RR), tidal volume (VT), minute volume (VM), and central respiratory neuromuscular drive as determined by inspiratory occlusion pressure (IOP) during increasing fractional inspired concentrations of carbon dioxide (FiCO2) in conscious dogs.

Animals—6 healthy dogs (3 males and 3 females).

Procedure—Dogs were administered 0, 5, or 10 µg of medetomidine/kg IV. We measured RR, VT, VM, and IOP for the first 0.1 second of airway occlusion (IOP0.1) during FiCO2 values of 0%, 2.5%, 5.0%, and 7.5% at 15 minutes before and 5, 30, and 60 minutes after administration of medetomidine.

Results—Increases in FiCO2 significantly increased RR, VT, and VM. The IV administration of 5 and 10 µg of medetomidine/kg significantly decreased RR and VM at 5, 30, and 60 minutes for FiCO2 values of 2.5% and 5.0% and at 30 and 60 minutes for an FiCO2 value of 7.5%. The IOP0.1 was decreased after 30 minutes only for an FiCO2 value of 7.5% in dogs administered 5 and 10 µg of medetomidine/kg. The IOP0.1 was decreased at 60 minutes after administration of 10 µg of medetomidine/kg for an FiCO2 value of 7.5%.

Conclusions and Clinical Relevance—The IV administration of medetomidine decreases RR, VM, and central respiratory drive in conscious dogs. Medetomidine should be used cautiously and with careful monitoring in dogs with CNS depression or respiratory compromise. (Am J Vet Res 2004;65: 720–724)

Full access
in American Journal of Veterinary Research